Pharmaceuticals company Caplin Point Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Gross Margin: 60% vs. 56.6% in Q4FY24 — aided by new product launches across existing and new markets. Revenue from Operations: Rs 502.5 crore vs. Rs 453.2 crore in Q4FY24 — up 10.9% YoY. EBITDA: Rs 193.8 crore vs. Rs 162.5 crore in Q4FY24 — up 19.2% YoY. EBITDA Margin: 36.7% vs. 34.5% in Q4FY24 Profit After Tax (PAT): Rs 145.3 crore vs. Rs 121.2 crore in Q4FY24 — up 19.8% YoY. FY25 Financial Highlights: FY25 Total Revenue at Rs 2034 crore; an increase of 15.5% YoY FY 25 PAT at Rs 541 crore; (Growth of 17.3% over FY24) EBITDA Margin: 36.5% vs. 35.1% in FY24 Basic EPS increased by 17.2% to Rs 70.57 in FY25 compared to Rs 60.19 in FY24. Cash Flow from Operations in FY25 is Rs 432.39 crore vs Rs 318 crore in FY24. CSL's Total revenue crosses Rs 366 crore, an increase of 15% over FY24. US Market FY25 EBIDTA crosses Rs 102 crore (Growth of 71% over FY24) Free Cash Reserves at Rs 1,180 crore; Liquid Assets at Rs 2,148 crore Commenting on the performance, C.C. Paarthipan, Chairman said: "We’re delighted to close out another year with excellent Top and Bottom Line Growth, and continue our progress on being a benchmark when it comes to Cashflows. Our front end in the US is taking shape at a good pace and we expect this entity to drive strong growth for the parent company over the next few years. We’re once again focusing on getting back to Asset Light outsourcing using our Second Innings at China, with import of Peptides and Key starting materials for Biosimilars, which we plan to file and launch in our Emerging Markets where we have a significant presence already. With our API entities coming on stream in the very near future, we can truly envision Caplin being a fully integrated global Pharma player in the years to come." Result PDF